Lv12
20 积分 2022-08-06 加入
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
3小时前
已完结
Characteristics and utilization of the three BCMA-targeted therapies in multiple myeloma
21小时前
已完结
The multiple myeloma drug market
1天前
已完结
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?
1天前
已完结
ATR/CHK1 inhibitors and cancer therapy
2天前
已完结
Expression of delta-like protein 3 is reproducibly present in a subset of small cell lung carcinomas and pulmonary carcinoid tumors
23天前
已完结
DNA polymerase θ is preferentially expressed in lymphoid tissues and upregulated in human cancers
23天前
已完结
Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy
25天前
已完结
DNA replication stress and emerging prospects for PARG inhibitors in ovarian cancer therapy
27天前
已完结
The DNA damage response and cancer therapy
28天前
已完结
皖公网安备34019202002308
